Abstract: Neuritin (Nrn1) is a neurotrophic factor that plays various roles in neural development and synaptic plasticity. In this study, the NRN1 gene was cloned and expressed in Escherichia coli and then recombinant neuritin protein was purified so that its neurobiological activity could be evaluated. The protein, which was obtained at a concentration of 0.45 mg/ml and > 90% purity, had the predicted molecular weight of 30 kDa, as determined via sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blot analysis confirmed that an anti-neuritin antibody could recognize the fusion protein. Subsequent functional analyses revealed that recombinant neuritin promoted neurite outgrowth in embryonic chicken dorsal root ganglia and PC12 cells. These results suggest that recombinant neuritin protein could be a valuable tool for inducing neurite regeneration, for instance in cases of spinal cord injury or neurological diseases.
INTRODUCTION
Neuritin 1 is an extracellular glycophosphatidylinositol-linked protein that stimulates axonal plasticity, dendritic arborization and synapse maturation in the central nervous system (CNS). It is also named candidate plasticity 15 (CPG15). Human neuritin is located within the 6p24-p25 interval of chromosome 6 [1] , with a 429-bp open reading frame (ORF) that encodes a 142-amino acid protein.
Neuritin inhibits neuronal degeneration and apoptosis [2, 3] and stimulates neuronal migration [4, 5] and the development and maturation of visual cortical neurons [6, 7] . These findings suggest that neuritin has potential for the treatment of neurological diseases and injuries [8] . However, its low cellular concentrations prohibit its extraction and purification in therapeutically useful quantities. Cell-based expression systems are an effective way to prepare large amounts of a desired protein. To the best of our knowledge, there are no reports of high yields of full-length neuritin obtained using bacterial expression systems. Therefore, we developed a T7 promoter-driven recombinant expression system for producing thioredoxin-tagged human neuritin protein in BL21 Escherichia coli. The system uses the pET32a(+) expression plasmid to obtain milligram amounts of highly purified neuritin protein for further investigation of its biological functions.
MATERIALS AND METHODS
Bacterial strains, plasmids, and cell lines BL21 (DE3) competent E. coli cells and pET-32a(+) plasmid (Novagen) were used for cloning and protein expression. PC12 cells were purchased from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences. Trypsin, horse serum and fetal bovine serum (FBS) were purchased from Invitrogen. White Leghorn chicken embryonic day 8 embryos were purchased from Breeding Bird Farms in Shihezi, China and used for the isolation of dorsal root ganglia (DRG) as previously described [9] . All of the procedures were conducted according to the ethical guidelines of Shihezi University. All other reagents were of analytical grade and obtained from commercial sources.
Plasmid construction
The ORF of Nrn1 (GenBank accession number NM016588.2) was amplified via PCR using pcDNA3.1-His-neurtrin as a template with the following primers: 5'-GCG CCA TGG GAC TTA AGT TGA ACG GCA G-3' (forward) and 5'-TAG CGG CCG CTC AGA AGG AAA GCC AGG-3' (reverse). The NcoI and NotI restriction sites are underlined. The reaction conditions were as follows: 95ºC for 4 min; 30 cycles of 95ºC for 60 s, 63ºC for 30 s, and 72ºC for 60 s; and 72ºC for 10 min. The length of the PCR product was verified using 1.5% (w/v) agarose gel electrophoresis prior to cloning into the NcoI and NotI sites of the pET32a(+) plasmid. The insert sequence was verified via DNA sequencing at the Beijing Genomics Institute in Shenzhen, China.
Expression and purification of recombinant fusion protein BL21 (DE3) E. coli cells were transformed with pET32a-neuritin plasmid. A single colony was inoculated in 10 ml lysogeny broth (LB) supplemented with 100 μg/ml ampicillin and grown overnight at 37ºC. The culture was diluted 1:100 with fresh lysogeny broth containing ampicillin and grown for 2.5-3 h with shaking at 37ºC. When the optical density at 600 nm reached 0.8, protein expression was induced with 0.1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were cultured at 37ºC for an additional 2, 4 or 6 h, and then collected by centrifugation at 8,000 × g for 10 min at 4ºC. The pellets were resuspended in lysis buffer consisting of 50 mM Tris-HCl (pH 8.5-9.0), 2 mM EDTA, 100 mM NaCl, 0.5% Triton X-100 and 0.1 mg/ml lysozyme, and incubated at room temperature for 15 min and then on ice for 30 min. The cells were lysed by sonication on ice at 300 W for 60 cycles consisting of 2 s of sonication at 3-s intervals. The lysate was centrifuged at 8,000 × g for 30 min at 4ºC, and both the supernatant and pellet were retained for analysis. After confirming sufficient protein induction, recombinant neuritin was purified using a nickel-nitrilotriacetic acid (Ni-NTA) purification kit (Qiagen) according to the manufacturer's instructions. Protein concentration was determined using the Bradford method with bovine serum albumin as a standard.
SDS-PAGE and western blot analysis
Protein samples were separated using 12% (v/v) SDS-PAGE and gels were stained with Coomassie Blue R-250 (Thermo Scientific). Alternatively, proteins were transferred to a polyvinylidene difluoride membrane (23 V for 50 min) and western blot analysis was performed using polyclonal rabbit anti-human neuritin and horseradish peroxidase-conjugated goat anti-rabbit IgG secondary antibodies.
Analysis of PC12 cells and DRG morphology
PC12 cells in logarithmic growth phase were detached from culture plates with 0.25% (v/v) trypsin/0.02% (v/v) EDTA, resuspended in F-12K culture medium containing 15% (v/v) horse serum and 2.5% (v/v) FBS, and counted under an Olympus inverted microscope. Passaged cells were seeded at a density of 6 × 10 3 in 96-well culture plates (100 μl/well) and cultured in a 5% CO 2 incubator at 37ºC for 24 h. Cells were then treated with neuritin at a final concentration of 40 μg/ml. The controls were mock fusion protein at a final concentration of 40 μg/ml purified using the same method as for neuritin or 25 μl phosphate-buffered saline (PBS) with 100 µl culture medium. Morphological changes were assessed under an inverted microscope 72 h posttreatment. The 50 longest neurites in 10 random fields were measured. DRG were harvested from fertilized chicken eggs after incubation for 8-9 days, placed in 96-well poly-L-lysine-coated plates (2-3 DRG/well), and cultured in 200 μl Dulbecco's modified Eagle's medium containing 5% (v/v) calf serum. Recombinant neuritin or mock fusion protein (40 µg/ml) was then added to the wells and neurite outgrowth was measured 72 h later by tracing arbors from the soma perimeter to the neurite tips. The 50 longest neurites were measured in individual DRG as previously described [10] .
Statistical analysis
Data from three independent experiments were traced and described with ImageJ (U.S. National Institute of Health) and GraphPad Prism 5.0 (GraphPad Inc.) software. They are expressed as means ± standard deviation. Significant statistical differences were determined using t-test analysis of variance on SPSS software (IBM). In all cases, p < 0.05 was considered statistically significant.
RESULTS

Plasmid construction
The fragment amplified via PCR was approximately 450 bp (Fig. 1A) . Following ligation and transformation, the pET32a-neuritin plasmid was digested with NcoI and NotI and resolved via electrophoresis. This revealed two bands of approximately 5900 and 450 bp (Fig. 1B) . The insert sequence was confirmed using the NCBI nucleotide database local alignment search tool, BLAST. 
Expression and purification of recombinant thioredoxin-neuritin
The thioredoxin-neuritin fusion protein containing an N-terminal 6×-His tag and enteropeptidase cleavage site was expressed in BL21 (DE3) E. coli transformed with the pET32a-neuritin plasmid. SDS-PAGE showed that IPTG induction yielded a specific protein band with a molecular weight of approximately 30 kDa, consistent with the predicted molecular weight of neuritin. The optimal induction conditions were 0.1 mM IPTG for 4 h at 37ºC (Fig. 2) . Nearly all of the induced protein localized to insoluble inclusion bodies. Then neuritin was renatured by dialyzing at 4ºC against refolding buffer (10 mM TrisHCl, 3 mM glutathione and 0.6 mM oxidized glutathione) containing 4, 3, 2, 1, and 0 M urea (dialysis with 4 M for 12 h, intermediate concentrations for 4 h each, and 0 M for 8 h). After Ni-NTA column purification, the protein purity was > 90% (Fig. 3A) . Western blot analysis confirmed that the purified fusion protein was neuritin 1 (Fig. 3B) . 
Recombinant thioredoxin-neuritin induces neurite outgrowth in PC12 cells and DRG
The cellular morphology of PC12 cells and DRG cultured in the presence of recombinant neuritin for 72 h was visualized via microscopy ( Fig. 4A) . As expected, PC12 cells cultured in PBS or with mock protein as a control were small, round and lacked neurites, whereas those treated with neuritin showed obvious processes that formed a network structure. Similarly, there was little to no neurite outgrowth from DRG in the PBS and mock protein treatment groups. By contrast, extensive protrusions were observed in DRG treated with neuritin. These were significantly longer (p < 0.05) than those in the control cultures (Fig. 4B) .
DISCUSSION
Neuritin exists in two forms: as a membrane protein that is anchored to the cell membrane via the GPI domain and as a soluble protein that is generated via cleavage of the signal peptide. The difficulty of achieving large-scale expression of active full-length neuritin is a major obstacle for investigators. E. coli expression systems are widely used to obtain large quantities of recombinant protein, owing to the well-described genetic background of the bacterium, ease of manipulation, and relatively low cost [11] . The pET32a plasmid is a T7 phage lac promoter-based protein expression vector that contains N-terminal Trx and 6×-His sequences. The latter allows Ni 2+ -affinity purification of the resultant fusion protein [12, 13] . In our study, E. coli cultures were incubated with 0.1 mM IPTG at 37ºC for 4 h, which yielded maximum protein expression (> 40% of total bacterial protein). After Ni-NTA affinity purification, refolding, concentration, and quantitative electrophoresis, a recombinant neuritin protein solution of 0.45 mg/ml and purity > 90% was obtained. Neuritin has various functions in the nervous system: stimulating neurite growth and synapse formation and maturation [14, 15] ; inducing visual cortical neuron development and maturation; preserving motor neuron viability; and promoting neural progenitor cell survival [16, 17] . Overexpression of hNRN1 in vivo can promote survival of RGCs and revive the regenerative ability of injured axons [18] . The biological activities of neurotrophic factors are typically assessed in PC12 and DRG culture systems or in sciatic nerve injury models [19] [20] [21] . In this study, we attempted to use a recombinant enterokinase kit to remove the His tag, but this was unsuccessful due to the enzyme's low digestion efficiency. To exclude any effects of the epitope tag, we induced E. coli transformed with the pET32a empty plasmid and used the purified tag as a mock control in PC12 cells and DRG cultures. There were no neurites observed in either control group, but cultures treated with neuritin exhibited extensive neurite outgrowth. These results are consistent with previous reports [22, 23] . They indicate that neuritin and fulllength neuritin perform partially similar functions. Additional research is needed to investigate similarities and differences in the regulation of gene expression and the physiological functions for both membrane-bound and soluble proteins.
In summary, we constructed a pET-32a-neuritin prokaryotic expression vector and successfully purified neuritin protein with biological activity. The results of this study provide a foundation for future analyses of the biological function of human neuritin and for investigations of its therapeutic applications in cases of nervous system injury or disease.
